Business Context and Reporting Period
Company: iBio, Inc. (formerly iBioPharma, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: iBio is a biotechnology company focused on commercializing its proprietary iBioLaunch platform for producing biologics, including vaccines for H1N1 and H5N1 influenza. The company discontinued its nutritional supplement business effective April 1, 2009, transferring those assets to a former parent in exchange for a 5% royalty. The company is currently a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2010 | Nine Months Ended Mar 31, 2010 | Balance Sheet (Mar 31, 2010) |
|---|---|---|---|
| Sales/Revenue | $0 | $0 | N/A |
| Net Loss | $(1,644,279) | $(3,495,312) | N/A |
| Operating Loss | $(1,592,643) | $(2,922,017) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1,494,976 |
| Total Assets | N/A | N/A | $5,476,805 |
| Total Liabilities | N/A | N/A | $1,878,812 |
| Working Capital | N/A | N/A | $(328,773) |
| Derivative Liability | N/A | N/A | $799,204 |
Note: Working capital is negative primarily due to the classification of warrants as a derivative liability ($799,204) rather than equity.
Material Changes vs. Prior Period
- Revenue: Sales dropped to $0 for the three and nine months ended March 31, 2010, compared to $326,886 and $1,039,446 in the prior year periods. This is due to the complete discontinuance of the nutritional supplement business in April 2009.
- Operating Expenses:
- R&D: Increased significantly to $1,055,986 (3-month) and $1,414,370 (9-month) from $83,100 and $714,300, respectively. The increase is driven by a $1 million payment to FhCMB for research services and hiring a Chief Scientific Officer.
- G&A: Increased to $536,657 (3-month) and $1,507,647 (9-month) due to higher financial advisory and investor relations fees associated with operating as a standalone public entity.
- Non-Cash Derivative Expense: A significant non-cash expense of $58,385 (3-month) and $599,815 (9-month) was recorded due to the change in fair value of derivative instruments (warrants) following the adoption of ASC 815-40. This liability increased from $199,389 at adoption (July 1, 2009) to $799,204 at March 31, 2010.
- Cash Position: Cash increased by $455,732 to $1,494,976, driven by $2,795,887 in proceeds from a September 2009 equity offering, partially offset by operating and investing cash outflows.
Guidance, Outlook, Risks, and Contingencies
- Liquidity and Going Concern: Management states that current cash resources are expected to support operations only through the summer of 2010. The company faces a "going concern" uncertainty and requires additional equity or debt financing to continue beyond that date.
- Outlook: The company expects at least one vaccine candidate to begin Phase 1 clinical trials in calendar year 2010. Future funding is planned through licensing arrangements or equity sales.
- Material Weakness in Internal Controls: The independent auditor (J.H. Cohn LLP) identified a material weakness in internal controls over financial reporting regarding non-routine, complex transactions. This led to a restatement of the September 30, 2009 financial statements due to delayed implementation of ASC 815-40. Management is implementing remediation measures.
- Commitments: The company has a commitment to pay FhCMB $10 million over five years ($1 million per installment). The April 2010 installment was unpaid as of the filing date due to cash flow constraints.
- Contingencies: A $250,000 dispute regarding a technical milestone with FhCMB was resolved in the prior quarter, with the amount recorded as an expense and accrued liability.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure funding before the summer of 2010 to avoid operational delays or liquidation.
- Derivative Liability Volatility: Monitor the fair value of the $799,204 derivative liability, as it is highly sensitive to stock price fluctuations and will continue to impact net loss non-cashly until warrants expire or are exercised.
- Internal Control Remediation: Confirm the effectiveness of the new internal review processes established to address the material weakness identified by auditors.
- FhCMB Payment Status: Track the payment of the overdue $1 million installment to FhCMB due in April 2010 and the impact on the research agreement.
- Equity Dilution: Assess the potential for significant shareholder dilution if the company raises capital through equity issuance to fund operations.